Oversubscribed Round and Consortium of Renowned Investors
The Berlin-based neurotech startup Nuuron has raised €3.5 million in an oversubscribed seed financing round. The round is led by High-Tech Gründerfonds (HTGF) and includes investors such as IBB Ventures, caesar., the Business Angel Club Berlin, other business angels and family offices. In addition, Nuuron entered a strategic partnership with RoX Health, a subsidiary of the pharma and diagnostics group Roche.
Clinical Trials with Charité and DZNE – Market Entry in Europe and the U.S.
Nuuron will use this funding for animal studies in collaboration with the German Center for Neurodegenerative Diseases (DZNE) and a clinical trial with Alzheimer’s patients at Charité, and to advance product development. Additionally, market entry preparations start in Europe and the U.S.
„Our scientists have succeeded in hacking the neural code of memory, enabling us to develop a digital drug to treat Alzheimer’s Disease.“
Nuuron Has Hacked the Neural Code of Memory
„Our scientists have succeeded in hacking the neural code of memory, enabling us to develop a digital drug to treat Alzheimer’s Disease. We call it the Memory Pacemaker – an effective therapy, prescribed by doctors and reimbursed by health insurances,“ explains Dr. Markus Müschenich, co-founder of Nuuron.
A New Therapy Option for 100+ Million Alzheimer’s Patients
Currently, over 55 million people worldwide live with Alzheimer’s Disease and other dementias, a number expected to rise to 139 million by 2050. The market for Alzheimer’s therapies was estimated at USD 5.8 billion in 2023, with a projected increase to USD 11.4 billion by 2032.
Nuuron Demonstrates the Immense Potential of Digital Drugs
„We at RoX Health have supported Nuuron from the very beginning in a strategic collaboration, as we recognized the immense potential of their technology early on. Nuuron’s innovative approach demonstrates the possibilities that digital therapeutics offer and how we can treat complex diseases even more effectively in the future.“ – Dr. Robert Schnitzler, CEO, RoX Health, Berlin & Head Digital Health Innovation, Roche Pharma AG
